The Blue Ocean Pharma Management Team consists of industry professionals who have worked together for upwards of 10 years. The longevity of these relationships has allowed us to establish working relationships that foster growth and promote the evolution of our company to address changing market needs. We have a united goal of ensuring the success of our client partners, while supporting optimal patient care. Importantly, to achieve this we are committed to continually adapting to the changing healthcare marketplace, evolving as an organization and as individuals.

Alden E. Masonis, PhD

Founding Partner

Alden received his doctoral degree from a joint program in neuropharmacology between Rutgers University Graduate School and the University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School. His thesis research established the first evidence for a direct interaction between androgenic and anabolic steroids and the gamma amino butyric acid receptor system in rat brain, establishing a potential link between the immediate effects of androgenic hormones and one of many neurotransmitter receptor systems in the central nervous system.

He subsequently entered a postdoctoral research program in neuroendocrinology and reproductive physiology at the Oregon Health Sciences University in Portland, Oregon. Following his postdoctoral research appointment, Alden joined the medical communications industry, working in both medical advertising and medical communications. In 1997, he was involved in establishing a US office for the UK-based agency Medical Action Communications (MAC). As Senior Vice President, Strategic Development, Alden was responsible for the creation of a publications planning resource at MAC, which grew to represent approximately 50% of the company's business. In 2001, Alden joined Helix Medical Communications, a subsidiary of AXIS Healthcare Communications, as Managing Director and was responsible for opening an office in New Jersey as well as a presence in London, UK.

In October 2006, Alden left Helix to establish a joint venture with Founding Partner Donna J. Schroeder: Percolation Communications LLC, focusing on the application of proven theories and processes to medical marketing strategy development. Since its original launch in 2006, Percolation Communications has grown to offer a vast array of services that suggested the need to establish independent business units that could offer specialized services reflecting their client-partners' needs and team members' individual talents. As a result, in 2011 Alden and Donna launched two new businesses to join Percolation – i.e. Strategy LLC and Powered 4 Significance LLC – under the parent company Blue Ocean Pharma LLC. This family of companies provides client partners with a library of specialized services that address needs across the product lifecycle, including clinical development, commercialization, and medical/marketing communications. The specialized businesses in the Blue Ocean Pharma group share the unified goal of ensuring the success of their client partners while supporting optimal patient care.

Donna J. Schroeder, PharmD

Founding Partner

Donna received her PharmD degree from the University of California, San Francisco (UCSF), where she also completed 2 years of residency. Her first residency was in hospital and clinical practice and her second in healthcare administration. Subsequent to her residencies, Donna entered into a national faculty appointment search and was selected by UCSF as a tenured professor with both academic and clinical responsibilities. Donna was appointed as the Director of the Drug Information Analysis Service (DIAS), where she ran programs on two campuses (Parnassus and Laurel Heights) as well as taught the drug information course for third- and fourth-year PharmD candidates. In addition to her responsibilities for the DIAS, Donna was responsible for preceptorship of fourth-year students on the General Medicine and HIV wards, as well as serving as clinical pharmacist on the oncology ward.

In 1994, Donna joined several faculty members from UCSF at OnCare, a physician practice management organization. OnCare and Oncology Therapeutics Network joined forces to provide clinical and contracting services for community medical oncology practices. Donna's responsibilities included developing a comprehensive set of evidence-based clinical guidelines for 90% of the tumor types treated in the community setting. The treatment guidelines were aligned with the format of the National Comprehensive Cancer Network and were peer-reviewed by national experts and community practitioners. These two experiences (drug information and guideline development and expert panel facilitation) formed the basis for her interest in a medical communications career.

Donna began that career as a Medical Director at Churchill Communications and was promoted within 2 years to Managing Director of the West Coast operations in Los Altos, CA. In 2001, Donna founded Helix Medical Communications and with valuable contributions from her managing directors and senior management team, grew Helix to be an international company with four offices in the United States and Europe and gross revenues of over $18M. Donna has lectured nationally and internationally on issues of concern to clinicians and the pharmaceutical industry alike as they pertain to strategic yet fair-balanced information presentation and dissemination.

In October 2006, Donna left Helix to establish a joint venture with Founding Partner Alden E. Masonis, focusing on the application of proven theories and processes to medical marketing strategy development. Blue Ocean Pharma provides unified focus on the delivery of value-added medical marketing strategy and scientific strategy services to pharmaceutical and biotechnology company partners.

Throughout her career in medical communications and strategic consulting, Donna has demonstrated excellent client-service skills by integrating her clinical background and her strategic business acumen. Given her professional career history, publications-related activities, especially in the oncology arena, are her forte. Donna also has significant experience in CNS medicine (restless leg syndrome, multiple sclerosis, spasticity, neuropathic pain, low back pain, and ADHD), HIV/AIDS, autoimmune disorders, hematology, endocrinology, and cardiology, with relevant thought leader relationships in all of these areas.

Paul Fanelli

Director, Editorial Services

Paul joined Percolation Communications in July 2011 as Editorial Director and is responsible for oversight of editorial quality at all the Blue Ocean Pharma companies. Starting in 2005 he had been at Helix Medical Communications in the San Mateo, CA, office, where he supervised a group of full-time in-house editors, in addition to hands-on editorial project work. At Helix he and his staff edited and executed the submission of dozens of articles to peer-reviewed journals, many abstracts and posters, slide presentations, competitive intelligence newsletters, advisory board meeting materials, and numerous other projects.

Paul came to Helix after a number of years as an editor and editorial supervisor in the medical advertising field. After beginning at FCB HealthCare, he moved to Harrison Wilson & Associates, where he helped in the establishment of a San Francisco office, including the hiring of an editorial staff and creation of in-house processes and style guides. He has also been an editor at Lena Chow Euro RSCG and at the American Academy of Ophthalmology, where he worked on online educational publications for academy members.

Therapeutic areas Paul has familiarity with include cardiology, ophthalmology, oncology, and dermatology, among others. He also has experience in traditional typography and legal publishing. He has a BA in German literature (biology minor) from Colby College.

Follow us on: